Skip to main content

Advertisement

Table 1 Candidate demographics, cPRA and clinical outcomes

From: B cell repertoires in HLA-sensitized kidney transplant candidates undergoing desensitization therapy

  Controls (n = 7) Responders (n = 11) Non-responders (n = 8)
Age (years) 45 ± 11 40 ± 12 43 ± 7
Male/female 4/3 7/4 2/6
Race
 White 3 3 4
 Black 1 3 1
 Hispanic 1 1 3
 Asian 2 3 0
 Native American 0 1 0
Cause of ESRD    
 Diabetes 0 2 1
 Glomerulonephritis 4 1 1
 SLE 1 3 1
 PKD 0 1 1
 Congenital 0 3 0
 Other 2 1 4
Cumulative cPRA (%)
 Before desensitization 13 ± 16 97.4 ± 2.7 100 ± 0
 After desensitization N/A 87.9 ± 3.8 100 ± 0
Transplanted (%) 7 (100) 11 (100) 3 (37.5)
Donor type: DD:LUR:LRD 1:0:6 8:2:1 2:1:0
Rejection
 Borderline acute 0 3 (27) 1 (33)
 Cell mediated 0 1 (9) 0
 Antibody mediated 0 0 0
Graft loss (%) 0 0 0
Death-censored graft survival (1 year) 100% 100% 100%
  1. SLE systemic lupus erythematosus, PKD polycystic kidney disease, DD deceased donor, LUR living unrelated, LRD living related donor